Pharmaceuticals

Zoetis

FactSet Survey: Analysts Cut ZTS Median Price Target to $117

Zoetis released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 2.262 B (forecast USD 2.301 B), actual EPS USD 1.42 (forecast USD 1.5366)

Zoetis Reports Q1 2026 Earnings

Zoetis Reports Q1 Earnings Per Share of $1.42

Roberts Stephens Wealth Management significantly increased its holding of Zoetis stock

Oppenheimer Increases Holdings in Zoetis

Zoetis to Release FY2026 Q1 Earnings on May 7 Pre-Market (EST), Forecast Revenue USD 2.301 B, EPS USD 1.5366

UBS Downgrades Zoetis Price Target to $130 Maintains Neutral Rating

James Investment Research Inc. Reduced Holdings in Zoetis

Marathon Capital Management Increased Holdings of Zoetis Inc. in Q4

Montrusco Bolton Investments Inc. Significantly Increased Holdings of Zoetis Inc. in Q4

Zoetis Reports Third Quarter 2025 Earnings and Adjusts Full-Year Guidance

Zoetis Announces Q4 2024 Earnings and a New $6B Stock Repurchase Program

Tritonpoint Wealth LLC Significantly Reduced Its Holdings in Zoetis Inc.

Scott & Selber Inc. Increased Holdings in Zoetis Inc.

Renaissance Investment Group LLC Reduces Holdings in Zoetis

Agricultural Credit Union Increases Holdings in Zoetis Inc.

First Long Island Investors LLC reduced holdings in Zoetis Inc.

Zoetis to Acquire Neogen's Animal Genomics Business for $160 Million

Zoetis Reports 2025 Earnings and Outlines 2026 Outlook

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Zoetis Inc. (ZTS.US) Q4 2024 Earnings Conference Call

Zoetis Inc. (ZTS.US) Q3 2024 Earnings Conference Call

MNDY

PAWZ

Investors are focusing on quarterly earnings for stock picks. Wix (WIX) hit a 52-week low, facing short selling due to AI competition. Monday (MNDY) reported $49 million in Q1 operating profit, with Q2 revenue guidance up to $356 million. Zoetis (ZTS) also reached a 52-week low, with a 10% growth in international revenue but an 8% decline in the U.S. market. Caution is advised for drug stocks as inflation impacts pet care spending.

Baystreet

Wix.com

Monday.com

Proshares Pet Care ETF

Weekly Stock Picks Starting on May 19, 2026

LABU

ARKG

IBBQ

Law Offices of Howard G. Smith is investigating potential securities fraud involving Zoetis Inc. (ZTS) after the company reported flat net income of $601 million for Q1 2026 and lowered its profit guidance. Following this news, Zoetis shares fell by 21.50% to $87.31. Shareholders who suffered losses are encouraged to contact the law firm for potential claims.

MorningStar

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

VG Health

iShares Biotechnology ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Health Care Select Sector SPDR

Zoetis Inc. (ZTS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

The Law Offices of Frank R. Cruz has announced an investigation into Zoetis Inc. (ZTS) for potential violations of federal securities laws following a significant drop in share price. On May 7, 2026, Zoetis reported flat net income of $601 million and lowered its profit guidance for the year, leading to a 21.50% decline in share price. Shareholders who lost money are encouraged to contact the law firm for potential claims.

Securities Fraud Investigation Into Zoetis Inc. (ZTS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

Zoetis Inc. (ZTS) shares fell 1.67% to $74.22 amid a poor trading day, with the S&P 500 down 1.24%. The stock remains 56.91% below its 52-week high of $172.23. Compared to competitors, Merck & Co. fell 1.79% and IDEXX Laboratories dropped 0.76%. Trading volume was 8.9 million, surpassing the 50-day average of 5.3 million.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Merck

IDEXX Labs

Zoetis Inc. Stock Outperforms Competitors Despite Losses On The Day

Shares of Zoetis Inc. (ZTS) rose 1.53% to $75.48 on a strong trading day, outperforming competitors like Merck & Co. (MRK), which fell 0.04%, and IDEXX Laboratories (IDXX), which rose 0.79%. The S&P 500 Index increased by 0.77%, while the Dow Jones Industrial Average rose by 0.75%. Despite the gains, Zoetis remains 56.17% below its 52-week high of $172.23 reached on June 3rd. Trading volume was 8.6 million, surpassing the 50-day average of 5.3 million.

Zoetis Inc. Stock Outperforms Competitors On Strong Trading Day

FTXG

PEPS

PepsiCo Inc. shares fell 1.70% to $149.27 on Wednesday, underperforming against competitors like Coca-Cola, which rose 0.29%. The S&P 500 Index increased by 0.58%, while the Dow Jones Industrial Average decreased by 0.14%. PepsiCo's stock is currently 12.95% below its 52-week high of $171.48 reached on February 12. Trading volume was 5.5 million, below the 50-day average of 6.1 million.

PepsiCo

First Trust NASDAQ Food & Beverage

Invesco Food & Beverage ETF

SPDR FD Consumer Staples

iShares US Consumer Staples ETF

VG Consumer Stap

Parametric Equity Plus ETF

Coca Cola

Starbucks

Mondelez

Factset Research

PepsiCo Inc. Stock Underperforms Wednesday When Compared To Competitors

Zoetis Inc. (NYSE: ZTS) has revised its full-year forecast, leading to a sharp decline of around 21.5% in its stock value in a single trading day. This decrease translates to a loss of about $23.91 per share for Zoetis shareholders. This development has resulted in a significant erosion of shareholder value for the company. The adjustments made by Zoetis have had a substantial impact on the market and investors, causing a substantial drop in the stock price.

Unusual Whales

Zoetis (ZTS) Securities Fraud Investigation - Levi & Korsinsky

Zoetis(ZTS.US)